Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration.

Area of Science:

• Pediatrics
• Emergency Medicine
• Pharmacology

Background:

• Parenteral rehydration is often required for pediatric patients with mild to moderate dehydration.
• Alternative rehydration methods are needed to improve patient comfort and reduce healthcare burden.

Purpose of the Study:

• To assess the efficacy, safety, and clinical utility of recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous rehydration in children.
• To evaluate the ease of subcutaneous access and procedure acceptance by clinicians and parents.

Main Methods:

• A phase IV, multicenter, single-arm study involving children aged 2 months to 10 years with mild/moderate dehydration.
• Patients received subcutaneous rHuPH20 followed by subcutaneous infusion of isotonic fluid.
• Rehydration success was defined by investigator attribution to subcutaneous infusion and discharge without alternative rehydration.

Main Results:

• Rehydration was successful in 94.1% of 51 pediatric patients.
• Initial subcutaneous catheter placement was successful in 90.2% of patients.
• No treatment-related systemic adverse events were reported; one serious adverse event (cellulitis) occurred.

Conclusions:

• rHuPH20-facilitated subcutaneous hydration is a safe and effective option for pediatric dehydration.
• The procedure demonstrates ease of use for clinicians and high satisfaction rates among parents.